Research institutionUnited Statesgog.org
The GOG Foundation (GOG) is an independent, non-profit clinical research organization focused on improving outcomes in gynecologic cancers, including ovarian, endometrial, cervical, and vulvar malignancies. The foundation advances patient care by designing, sponsoring, and conducting multi-center clinical trials across academic and community hospitals in the United States and internationally.
GOG provides scientific leadership and operational infrastructure for phase I–III studies, including protocol development, site activation and monitoring, data management, and analysis. It collaborates with investigators, cooperative groups, and biopharmaceutical companies to evaluate new therapeutics and treatment strategies, and disseminates evidence that informs standards of care and clinical guidelines in gynecologic oncology.
Also known as Gynecologic Oncology Group.
None yet. When a new project in the record names GOG as owner, partner or investor, it shows here.
Sofe‑M plus bevacizumab produced a 79% confirmed objective response rate and 100% disease control in platinum‑sensitive ovarian cancer, with activity across FRα levels and prior PARPi exposure.
Phase 3 RAINFOL‑02 shows statistically significant and clinically meaningful PFS and OS benefits versus investigator’s choice chemotherapy in platinum‑resistant ovarian cancer.
FDA grants Breakthrough Therapy status to sofetabart mipitecan for platinum-resistant ovarian cancer, based on promising Phase 1 results. Phase 3 trial underway.
